Pfizer asks USA regulators for emergency COVID-19 vaccine use

Cornelia Mascio
Novembre 21, 2020

A second covid-19 vaccine has shown to be nearly 95 per cent effective.

The Food and Drug Administration has not said how long it will take to study the vaccine data, but the government expects to give the green light for the vaccine in the first two weeks of December.

The speedy regulatory assessment comes as many European countries battle fierce new waves with the onset of colder weather, forcing governments to impose new lockdowns over tired populations.

Brussels is considering shelling out the euro equivalent of more $10 billion for the production of hundreds of millions of doses of candidate vaccines by CureVac and Pfizer-BioNTech, Reuters has reported, citing a European Union official said to be involved in the negotiations. The price it agreed for the Pfizer-BioNTech shot is 15.50 euros ($18.34) per dose, less than what the U.S.is paying, the newswire said.

Pfizer on Friday announced that it is moving ahead with its request of asking the USA regulators to allow emergency use of its Covid-19 vaccine, which has shown 95 per cent efficacy in a totality of two data sets released in the last 10 days.

In total, it's pre-ordered some 1.2 billion doses, according to a database run by the Duke Global Health Innovation Center.

The news echoed a similar announcement exactly one week ago from US pharmaceutical company Pfizer, which sent investors cheering with word that its vaccine candidate appeared to be more than 90 per cent effective.

The extraordinary results have sparked euphoria as the unprecedented compression of vaccine development timelines from years to months looks to be paying off.

The US government says it plans to vaccinate more than 20 million people in December, and then another 25-30 million per month.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE